Boehringer Ingelheim and Aster DM Healthcare have signed a strategic Memorandum of Understanding (MoU) to strengthen medical education, patient awareness, and early intervention for Cardio-Renal-Metabolic (CRM) diseases across the UAE.
The collaboration combines Boehringer Ingelheim’s expertise in CRM diseases with Aster DM Healthcare’s integrated healthcare network to improve clinical knowledge, support preventive screening, and empower patients through education and awareness initiatives.
Dr. Malathi Arshanapalai, Group Chief Medical Officer and Group Chief Quality Officer – Aster DM Healthcare, said:”At Aster, we believe that meaningful partnerships are instrumental in advancing healthcare. Our collaboration with Boehringer Ingelheim reflects our shared commitment to empowering healthcare professionals, improving patient education, and promoting earlier intervention through awareness and screening. By working together, we hope to drive better health outcomes and make a lasting impact on patients living with Cardio-Renal-Metabolic diseases across the region.”
Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE, Boehringer Ingelheim said: “Transforming lives for generations is at the heart of everything we do at Boehringer Ingelheim. As the burden of Cardio-Renal-Metabolic diseases continues to grow, it is becoming increasingly clear that these conditions cannot be addressed in isolation. Improving long-term outcomes requires a more interconnected approach – one that brings together healthcare providers, industry and patients to strengthen prevention, enable earlier intervention and deliver more coordinated care. Our collaboration with Aster DM Healthcare reflects this shared commitment and we hope to contribute to a more resilient healthcare ecosystem and create meaningful impact for patients and communities.”
Click here to join our WhatsApp channel here
The partnership’s first initiative is the Heart Failure Nurse Education Program, aimed at enhancing the skills of healthcare professionals and improving heart failure management. Future joint initiatives will focus on advancing healthcare education, preventive care, patient engagement, and earlier diagnosis to improve long-term outcomes for people living with chronic CRM conditions.
By fostering collaboration between healthcare providers and the biopharmaceutical industry, the partnership aims to support more coordinated care, strengthen healthcare capacity, and contribute to healthier communities across the UAE and Jordan.
Also read: Bahrain Advances $260 Million Medical City Project with New Strategic Contracts
